Clin Oncol | Volume 3, Issue 1 | Research Article | Open Access

Metabolic Therapy of Pancreatic Cancer

Prieto Gratacós E1, Alvarez1, Redal MA1,2*, Amador V1, Sosa I1, Laguzzi M1 and Pérez L1

1Department of Complementary Medicine, University of Buenos Aires, Argentina
2Department of Pharmacy and Biochemistry, University of Buenos Aires, Argentina

*Correspondance to: Redal MA 

Fulltext PDF

Abstract

ancreatic cancer mortality rates are the highest and most predictable ones. This pathology is considered to be uniformly fatal regardless of therapeutic approach. According to international data bases and several meta-analyses, the survival at one-year from diagnosis stands at 5% in European, Australian and New Zealand studies and at 29% in American studies, which include endocrine pancreatic cancer. Average survival time ranges from 4 to 6 months. For 98% of cases showing metastasis at the time of diagnosis, death occurs within six months.A metabolic treatment based on the nutri-pharmacological blockade of aerobic glycolysis (Warburg effect), and glutaminolysis, by means of a competitive inhibition of the rate limiting enzymes hexoquinase-2 (HK2), Lactate Dehydrogenase (LDHA) and Glutaminase (GS) through structural analogs of their physiological substrates, in the context of total blood glucose deprivation (Nuliglycaemia lucidae), seems to significantly prolong survival. This study describes the impact of the above-mentioned metabolic approach –as the sole form of therapy– on the one year survival rate and overall survival of 22 patients.

Keywords:

Pancreatic cancer; Metabolic therapy; Competitive inhibition; Structural analogs

Citation:

Prieto Gratacós E, Alvarez, Redal MA, Amador V, Sosa I, Laguzzi M, et al. Metabolic Therapy of Pancreatic Cancer. Clin Oncol. 2018; 3: 1512.

Subscribe to Our Newsletter